1.Name and nature of the underlying asset (e.g., land located at Sublot XX, Lot XX, North District, Taichung City): 5th and 6th floor of Taipei Bioinnovation Park (located at Sublot 1, Lot
Zhongnan , Nangang District, Taipei City)
2.Date of the occurrence of the event:2022/05/06
3.Transaction unit amount (e.g.XX square meters, equivalent to XX ping), unit price, and total transaction price:
Transaction amount:
Transaction volume is 2,635.6 ping. Evaluated amount of right-of-use asset is NT$387,552 thousand.
4.Trading counterparty and its relationship to the Company (if the trading counterparty is a natural person and furthermore is not a related party of the Company, the name of the trading counterparty is not required to be disclosed):Century Biotech Development Corporation
5.Where the trading counterparty is a related party, announcement shall also be made of the reason for choosing the related party as trading counterparty and the identity of the previous owner, its relationship with the Company and the trading counterparty, and the previous date and monetary value of transfer:Not applicable
6.Where an owner of the underlying assets within the past five years has been a related party of the Company, the announcement shall also include the date and price of acquisition and disposal by the related party, and its relationship to the Company at the time of the transaction:Not applicable
7.Projected gain (or loss) through disposal (not applicable for acquisition of assets; those with deferral should provide a table explaining recognition):Not applicable
8.Terms of delivery or payment (including payment period and monetary value), restrictive covenants in the contract, and other important terms and conditions:
The expected lease period is from 2022/11 to 2030/07, which is 7 years and 9 months in total. Further announcement regarding the terms and conditions will be made once the Company finished signing the contract.
9.The manner of deciding on this transaction (such as invitation to tender, price comparison, or price negotiation), the reference basis for the decision on price, and the decision-making department:The Company’s Board of Directors
10.Name of the professional appraisal firm or company and its appraisal price:Prudential Cross-Strait Real Estate Appraisers Firm
11.Name of the professional appraiser:LIN, JIN-SHENG
12.Practice certificate number of the professional appraiser:(94)TCG_NO.000060
13.The appraisal report has a limited price, specific price, or special price:Not applicable
14.An appraisal report has not yet been obtained:Not applicable
15.Reason for an appraisal report not being obtained:Not applicable
16.Reason for any significant discrepancy with the appraisal reports and opinion of the CPA:Not applicable
17.Name of the CPA firm:Not applicable
18.Name of the CPA:Not applicable
19.Practice certificate number of the CPA:Not applicable
20.Broker and broker’s fee:None
21.Concrete purpose or use of the acquisition or disposal:In response to the operation need, as laboratory and office in the future.
22.Any dissenting opinions of directors to the present transaction:None
23.Whether the counterparty of the current transaction is a related party:No
24.Date of the board of directors’ resolution:2022/05/06
25.Date of ratification by supervisors or approval by the audit committee:2022/05/06
26.The transaction is to acquire a real property or right-of-use asset from a related party:No
27.The price assessed in accordance with the Article 16 of the Regulations Governing the Acquisition and Disposal of Assets by Public Companies:Not applicable
28.Where the above assessed price is lower than the transaction price, the price assessed in accordance with the Article 17 of the same regulations:Not applicable
29.Any other matters that need to be specified:Further announcement will be made once the Company finished signing the contract.